Search results for "marker"

showing 10 items of 3799 documents

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C

2013

SUMMARY. Soluble CD36 (sCD36) plasma levels, a known marker of cardiometabolic disorders, are associated with surrogate markers of steatosis, while experimental and human studies show a link between CD36 expression in the liver and steatosis. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of sCD36 plasma levels with host and viral factors and sustained virological response (SVR). One hundred and seventy-five consecutive biopsy-proven patients were studied. sCD36 plasma levels were assessed by an in-house ELISA. All biopsies were scored by one pathologist for staging and grading (Scheuer) and graded for steatosis, which was considered moderate…

AdultCD36 AntigensMaleGenotypeBiopsyEnzyme-Linked Immunosorbent AssayLIVER FIBROSISHepacivirusCHRONIC HEPATITIS CAntigens CD36Settore MED/08 - Anatomia PatologicaAntiviral AgentsSeverity of Illness IndexPlasmaRibavirinHumansHEPATIC STEATOSISAgedSettore MED/12 - GastroenterologiaHepatitis C ChronicMiddle AgedFatty LiverLiverBiological MarkersFemaleInterferonsCD36 HCV steatosisBiomarkersINSULIN RESISTANCE
researchProduct

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

2012

Background & Aims Microparticles released into the bloodstream upon activation or apoptosis of CD4+ and CD8+ T cells correlate with inflammation as determined by histologic analysis in patients with chronic hepatitis C (CHC). Patients with nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH) can be differentiated from those with CHC based on activation of distinct sets of immune cells in the liver. Methods We compared profiles of circulating microparticles from patients with NAFL and NASH (n = 67) to those of CHC (n = 42), with healthy individuals (controls) using flow cytometry; the profiles were correlated with inflammation grade and fibrosis stage based on histologic an…

AdultCD4-Positive T-LymphocytesLiver CirrhosisMaleLymphocyteBiologyCD8-Positive T-LymphocytesChronic liver diseaseSeverity of Illness IndexArticleCell-Derived MicroparticlesDiagnosis DifferentialImmune systemFibrosisCell-Derived MicroparticlesNon-alcoholic Fatty Liver DiseasemedicineHumansAgedAged 80 and overInflammationHepatologyFatty liverBiopsy NeedleGastroenterologyAlanine TransaminaseHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFlow CytometryFatty Livermedicine.anatomical_structureAlanine transaminaseLiverROC CurveCase-Control StudiesImmunologybiology.proteinLinear ModelsFemaleBiomarkersGastroenterology
researchProduct

Immune profiling of Alzheimer patients

2011

Abstract Alzheimer's disease (AD) is characterized by extracellular senile plaques in the brain, containing amyloid-β peptide (Aβ). We identify immunological differences between AD patients and age-matched controls greater than those related to age itself. The biggest differences were in the CD4 + rather than the CD8 + T cell compartment resulting in lower proportions of naive cells, more late-differentiated cells and higher percentages of activated CD4 + CD25 + T cells without a Treg phenotype in AD patients. Changes to CD4 + cells might be the result of chronic stimulation by Aβ present in the blood. These findings have implications for diagnosis and understanding the aetiology of the dis…

AdultCD4-Positive T-LymphocytesMaleImmunosenescenceT cellImmunologyStimulationDiseaseCD8-Positive T-LymphocytesBiologyYoung AdultAlzheimer DiseaseExtracellularmedicineHumansImmunology and AllergySenile plaquesAgedAged 80 and overSettore MED/04 - Patologia GeneraleGene Expression ProfilingAβ42Age FactorsT cellCell DifferentiationImmunosenescenceMiddle AgedAlzheimer's diseasePhenotypeCD4 Lymphocyte Countmedicine.anatomical_structureNeurologyImmunologyEtiologyFemaleNeurology (clinical)BiomarkersJournal of Neuroimmunology
researchProduct

Phenotypic Alteration of Neutrophils in the Blood of HIV Seropositive Patients

2013

We have recently identified a novel population of activated low-density granulocytes (LDGs) in peripheral blood mononuclear cells of HIV seropositive patients. LDGs have a similar morphology to normal density granulocytes (NDGs), but are phenotypically different. Here we measured the expression levels of different phenotypic markers of granulocytes in the blood of HIV seropositive patients at different stages of HIV infection to determine whether the phenotype of NDGs and LDGs are affected by disease severity. Our results reveal that the phenotype of NDGs, but not that of LDGs, varies according to the severity of the disease.

AdultCD4-Positive T-LymphocytesMaleNeutrophilsHiv seropositivePopulationlcsh:MedicineHIV InfectionsDiseaseCD13 AntigensBiologyPeripheral blood mononuclear cellFlow cytometryYoung Adult03 medical and health sciences0302 clinical medicinemedicineHumansYoung adultlcsh:ScienceeducationSpecific Gravity030304 developmental biology0303 health scienceseducation.field_of_studyMultidisciplinaryArginasemedicine.diagnostic_testlcsh:RMiddle AgedViral LoadVirologyPhenotypeCD4 Lymphocyte Count3. Good healthPhenotypeImmunologyHIV-1lcsh:QFemaleViral loadBiomarkersResearch Article030215 immunologyPLoS ONE
researchProduct

Influence of training and a maximal exercise test in analytical variability of muscular, hepatic, and cardiovascular biochemical variables.

2014

Short, middle, and long-term exercise, as well as the relative intensity of the physical effort, may influence a broad array of laboratory results, and it is thereby of pivotal importance to appropriately differentiate the 'physiologic' from the 'pathological' effects of exercise. Therefore, the values of some biomarkers in physically active subjects may be cautiously interpreted since the results may fall outside the conventional reference ranges. It has been demonstrated that middle and long-term endurance and/or strenuous exercise triggers transient elevations of muscular and cardiac biomarkers. However, no data have been published about the effect of short-term maximal exercise test on …

AdultCalcitoninMalemedicine.medical_specialtyCardiac biomarkersCardiovascular biomarkersCalcitonin Gene-Related PeptideClinical BiochemistryPhysical ExertionPhysical medicine and rehabilitationReference ValuesInternal medicineNatriuretic Peptide BrainmedicineCreatine Kinase MB FormHumansAspartate AminotransferasesProtein PrecursorsMuscle SkeletalPathologicalExerciseRelative intensitybiologyL-Lactate Dehydrogenasebusiness.industryC-reactive proteinSkeletal muscleHeartGeneral Medicinegamma-GlutamyltransferaseLaboratory resultsPeptide FragmentsTroponinmedicine.anatomical_structureexercise; laboratory; biomarkersC-Reactive ProteinLiverCardiologybiology.proteinExercise TestPhysical EnduranceMaximal exerciseSedentary BehaviorbusinesslaboratoryBiomarkersScandinavian journal of clinical and laboratory investigation
researchProduct

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematolog…

2006

Abstract Purpose: LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Experimental Design: Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m2): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasm…

AdultCancer ResearchIndolesMaximum Tolerated Dosemedicine.drug_classApoptosisPharmacologyHydroxamic AcidsDrug Administration ScheduleHistonesStructure-Activity Relationshipchemistry.chemical_compoundPredictive Value of TestsPanobinostatAcute lymphocytic leukemiaPanobinostatBiomarkers TumormedicineHumansEnzyme InhibitorsAgedCell ProliferationAged 80 and overDose-Response Relationship Drugbusiness.industryHistone deacetylase inhibitorArea under the curveQTcF ProlongationMyeloid leukemiaMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseHypokalemiaHistone Deacetylase InhibitorsLeukemiaTreatment OutcomeOncologychemistryCinnamatesLeukemia MyeloidMyelodysplastic SyndromesAcute DiseaseInjections IntravenousImmunologymedicine.symptombusinessFollow-Up StudiesClinical Cancer Research
researchProduct

EGFR and PCNA experession in oral squamous cell carcinomas—a valuable tool in estimating the patient's prognosis

1993

We investigated 100 cases of oral squamous cell carcinomas immunohistologically with respect to the expression of the epidermal growth factor receptor (EGFR) and the proliferating cell nuclear antigen (PCNA). The results were correlated with a new malignancy grading of the invasive tumour areas and the clinical outcome of the patients to estimate the individual prognosis. In conclusion, the amount of antigen expression of both antigens increases with the increasing grade of malignancy of the oral squamous cell carcinoma. Furthermore, there is a statistically significant correlation between the amount of antigen expression and the patient's prognosis. An overexpression of EGFR and PCNA is as…

AdultCancer ResearchPathologymedicine.medical_specialtyMalignancyAntigenPredictive Value of TestsEpidermal growth factorProliferating Cell Nuclear AntigenBiomarkers TumormedicineHumansNeoplasm InvasivenessProspective StudiesEpidermal growth factor receptorSurvival analysisNeoplasm StagingMouth neoplasmbiologyPrognosismedicine.diseaseImmunohistochemistrySurvival AnalysisProliferating cell nuclear antigenErbB ReceptorsGene Expression Regulation Neoplasticstomatognathic diseasesTreatment OutcomeOncologyCarcinoma Squamous CellCancer researchbiology.proteinImmunohistochemistryMouth NeoplasmsEuropean Journal of Cancer Part B: Oral Oncology
researchProduct

Correlation of an estrogen receptor-related phosphoprotein with histopathological features in breast cancer.

1989

A series of 65 cases of different histological types of breast carcinoma was investigated for the immunohistochemical location of the estrogen receptor-related, 29 kD phosphoprotein using the ER-D5 monoclonal antibody.The ER-D5 response is heterogeneous in relation to some therapeutic limitations and is correlated with histopathological features of the tumors and survival. The main parameters for evaluation of breast cancers are reviewed, both those that are statistically correlated and those that are not apparently always correlated but are known to have considerable biological meaning, such as the ER-status of tumors.

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.drug_classClinical BiochemistryEstrogen receptorBreast NeoplasmsAdenocarcinomaMonoclonal antibodyPathology and Forensic MedicineCorrelationBreast cancermedicineBiomarkers TumorHumansNeoplasm InvasivenessAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseasePhosphoproteinsAdenocarcinoma MucinousCarcinoma PapillaryCarcinoma Intraductal NoninfiltratingOncologyReceptors EstrogenEstrogenPhosphoproteinImmunohistochemistrybusinessBreast carcinomaThe International journal of biological markers
researchProduct

Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.

2002

PURPOSE: To study safety, feasibility, and biologic activity of adenovirus-mediated p53 gene transfer in patients with bladder cancer. PATIENTS AND METHODS: Twelve patients with histologically confirmed bladder cancer scheduled for cystectomy were treated on day 1 with a single intratumoral injection of SCH 58500 (rAd/p53) at cystoscopy at one dose level (7.5 × 1011 particles) or a single intravesical instillation of SCH 58500 with a transduction-enhancing agent (Big CHAP) at three dose levels (7.5 × 1011 to 7.5 × 1013 particles). Cystectomies were performed in 11 patients on day 3, and transgene expression, vector distribution, and biologic markers of transgene activity were assessed by m…

AdultCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentGenetic enhancementGenetic VectorsUrologyCystectomyAdenoviridaeCystectomymedicineHumansNeoplasm InvasivenessAgedDNA PrimersBiologic markerAged 80 and overUrinary bladderBladder cancermedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryReverse Transcriptase Polymerase Chain ReactionGenetic transferGene Transfer TechniquesCystoscopyGenetic TherapyMiddle Agedmedicine.diseaseGenes p53medicine.anatomical_structureAdministration IntravesicalOncologyUrinary Bladder NeoplasmsImmunohistochemistrybusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry

2018

Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited.We analysed clinical data of 1712 patients diagnosed with BMs from breast cancer between January 2000 and December 2016 at 80 institutions.Median age at diagnosis of BMs was 56 years (22-90 years). About 47.8% (n = 732) of patients had HER2-positive, 21.4% (n = 328) had triple-negative and 30.8% (n = 471) had hormone receptor (HR)-positive, HER2-negative (luminal-like) primary tumours. The proportion of patients with HER2-positive BMs decreased comparing the years 2000-2009 with 2010-2015 (51%-44%), whereas the percenta…

AdultCancer Researchmedicine.medical_specialtyTime FactorsReceptor ErbB-2Posterior fossaAge at diagnosisBreast NeoplasmsTriple Negative Breast NeoplasmsYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerQuality of lifeRisk FactorsGermanyInternal medicineBiomarkers TumormedicineHumansRegistriesskin and connective tissue diseasesAgedRetrospective StudiesAged 80 and overBrain Neoplasmsbusiness.industryMiddle Agedmedicine.diseaseTreatment OutcomeOncologyHormone receptor030220 oncology & carcinogenesisCohortLife expectancyFemalePrimary breast cancerbusiness030217 neurology & neurosurgeryEuropean Journal of Cancer
researchProduct